TECH
SHORTBIO-TECHNE CORP
Research: Finviz ↗·Perplexity ↗
🗄 Viewing archived Q2 2026 data — frozen, no longer refreshed.
News Summary
NeutralBio-Techne announced a $11.3 billion acquisition by Merck KGaA at $73/share (June 25, 2026), which dominates the investment narrative going forward. Operationally, the company delivered mixed results with Q3 earnings miss followed by Q4 beat, flat full-year revenue growth, and persistent cell-therapy headwinds offset by strong growth in spatial biology (COMET >65% growth) and proteomics platforms, with management guiding to flat Q4 organic growth but mid-single-digit growth expected in FY2027 as biotech spending normalizes.
Red flags
- •Q3 FY2026 earnings missed consensus by $0.01 EPS and $4.7M revenue (1.49% shortfall)
- •Full-year FY2026 revenue flat year-over-year at $1.2 billion
- •11 analysts downwardly revised FY2027 earnings estimates; conservative guidance of $0.46-$0.60 EPS per quarter
- •Persistent near-term headwinds in emerging biotech spending and cell-therapy timing issues
- •Pending acquisition creates execution risk and uncertainty until close
Funds Reducing / Exiting (4)
| Fund | Manager | Shares Held | ∆ Shares | Position Value | % of Fund | QoQ | Status |
|---|---|---|---|---|---|---|---|
| Maverick Capital | Lee Ainslie | 1.5M | -3,203,927 | $108M | 2.9% | -68% | Existing |
| Durable Capital Partners | Henry Ellenbogen | 502K | -3,955,968 | $35M | 2.4% | -89% | Existing |
| Glenview Capital | Larry Robbins | 58K | -128,015 | $4M | 0.3% | -69% | Existing |
| Point72 | Steve Cohen | 0 | −295K | — | <0.1% | -100% | EXITED |
Shares Held reflects quarter-end positions for partial reductions. Funds that fully exited show 0 shares held. ∆ Shares is the change from the prior quarter. % of Fund is the prior-quarter position size — how much of the book was sold down.
Signal History
| Quarter | Direction | Funds | Score | vs SPY |
|---|---|---|---|---|
| Q2 2026 | SHORT | 4 | 3.86 | +3.9% |
| Q1 2026 | LONG | 3 | 3.85 | +19.1% |
Same issuer appearing in consecutive quarters — persistent institutional conviction. Returns are frozen at each archived quarter's last refresh.
Beneficial Ownership (13D/13G)
| Filer | Form | Shares | % of Class | Filed | Src |
|---|---|---|---|---|---|
| FMR LLC | SC 13G/A | 1.1M | 0.7% | 2026-11-05 | ↗ |
| FMR LLC | SC 13G/A | 12.8M | 8.1% | 2026-08-06 | ↗ |
| FMR LLC | SC 13G | 7.9M | 5.0% | 2026-05-06 | ↗ |
| Vanguard Capital Management | SC 13G | 11.6M | 7.4% | 2026-04-29 | ↗ |
SC 13D = active intent to influence control (10-day filing deadline after crossing 5%). SC 13G = passive accumulation, no intent to influence control.